BRCA2 reversion conferred resistance of castration-resistant prostate cancer cells to olaparib, consistently with previous studies in breast and prostate cancer patients showing acquired resistance to olaparib in BRCA2-associated cancers due to BRCA2 reversion mutations [45,46,47]. This evidence concerns the gene BRCA2 and prostate cancer.